VivoSim Labs, Inc. (VIVS): Cost of Revenue
$0
Year ended 2026-03-31
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $0 | -100.0% | 2026-07-14, From 2025-04-01 |
| 2025-03-31 | $5.0K | n/a | 2026-07-14, From 2024-04-01 |
| No annual figure between 2021-03-31 and 2025-03-31. | |||
| 2021-03-31 | $0 | -100.0% | 2021-06-15, From 2020-04-01 |
| 2020-03-31 | $328.0K | -32.0% | 2021-06-15, From 2019-04-01 |
| 2019-03-31 | $482.0K | -53.2% | 2020-05-28, From 2018-04-01 |
| 2018-03-31 | $1.03M | n/a | 2019-06-03, From 2017-04-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $0 | -100.0% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $108.3K | +575.0% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $42.0K | -75.6% |
| Pluri Inc. (PLUR) | 2026-06-30 | $563.0K | -17.4% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $3.96M | +220.1% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $1.36M | n/a |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $9.70M | n/a |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $2.2K | -50.1% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.32M | +94.2% |
Compare VIVS, ZIVO, ENTX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗